drugset / Trial / NCT04966676
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |